Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesoglycan is a natural glycosaminoglycan (GAG) preparation, a sulfated polysaccharide extract typically obtained from porcine intestinal mucosa, cow lung, or cow blood vessel (aorta). It is composed primarily of heparan sulfate, dermatan sulfate, and slow-moving heparin, with smaller, variable quantities of chondroitin sulfate. Mesoglycan is utilized for its multifaceted effects on the vascular system, including antithrombotic, profibrinolytic, anti-inflammatory, antiedema, and wound-healing properties. It is approved in many European countries for the treatment of various blood vessel homeostasis diseases and is also marketed as a dietary supplement. Its therapeutic applications span conditions such as peripheral arterial disease, chronic venous disease, leg ulcers, deep vein thrombosis, and cerebrovascular diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesoglycan.